The 65th ASH annual meeting and exposition took place on December 09-12, 2023, in San Diego, California.
The schedule at a glance is available here. This year’s event was primarily an in-person event with virtual broadcasts available.
Like last year, APLUSA exhibited in person with a physical booth. With this social media analysis, we will be assessing the impact of the conference online:
From the view of HCPs:
- Conditions most discussed during the listening period
- Posts that generated the most engagement
- Key trials mentioned
- A deep dive into the major developments presented during the conference
From the view of pharma companies:
- Top pharma companies (in terms of engagement and mentions) and the impact of their online communication including owned and earned mentions
- Insights into what has been communicated from the top pharma company-
Scope
The scope of the analysis is focused on mentions coming worldwide.*
There were a total of 11K mentions from HCPs and 502 mentions around pharma companies recorded during the listening period from December 2nd, 2023, to December 19th, 2023 (two weeks before and one week after the conference).
All mentions came from Twitter.
A total of 744 unique authors were identified.
*#ash23 OR #ash2023 OR #ASHTrainee OR #ASHkudos OR #ASHRunWalk OR #ASHaiku
Methodology
Volume of conversations
As usual, the peak of conversations happened during the conference representing 77% of mentions recorded during the listening period.
ASH23: Focus On HCPs
Tops hashtags
Share of Voice (SOV) of medical conditions most discussed (# of mentions): multiple myeloma, acute myeloid leukemia, and diffuse large B-cell lymphoma dominated online discussions.
👇 Read the full analysis and find out more focus about multiple myeloma and clinical trials. 👇
Find out more about Social Media Intelligence just here!